Effects of cannabidiol on schizophrenia-like symptoms in people who use cannabis

Morgan, Celia J. A.; Curran, H. Valerie

doi:10.1192/bjp.bp.107.046649

Cited by 261 publications

(191 citation statements)

References 12 publications

Supporting

Mentioning

172

Contrasting

Unclassified

Order By: Relevance

“…This effect has been attributed to THC. In agreement with the initial reports showing antagonism of THC-induced psychotomimetic effects [31,87,88], the presence of CBD in Cannabis strains has been shown to be protective against the occurrence of psychotic-like reactions and cognitive impairment [108][109][110]. In this context, Di Forti et al [111] found that the use of Cannabis containing high THC-and low CBD concentration was associated with a higher risk of a first psychotic episode.…”

Section: Cannabidiol and Psychosissupporting

confidence: 73%

Multiple mechanisms involved in the large-spectrum therapeutic potential of cannabidiol in psychiatric disorders

Campos

Moreira

Gomes

et al. 2012

Phil. Trans. R. Soc. B

346

237

View full text Add to dashboard Cite

Cannabidiol (CBD) is a major phytocannabinoid present in the Cannabis sativa plant. It lacks the psychotomimetic and other psychotropic effects that the main plant compound D 9 -tetrahydrocannabinol (THC) being able, on the contrary, to antagonize these effects. This property, together with its safety profile, was an initial stimulus for the investigation of CBD pharmacological properties. It is now clear that CBD has therapeutic potential over a wide range of non-psychiatric and psychiatric disorders such as anxiety, depression and psychosis. Although the pharmacological effects of CBD in different biological systems have been extensively investigated by in vitro studies, the mechanisms responsible for its therapeutic potential are still not clear. Here, we review recent in vivo studies indicating that these mechanisms are not unitary but rather depend on the behavioural response being measured. Acute anxiolytic and antidepressant-like effects seem to rely mainly on facilitation of 5-HT1A-mediated neurotransmission in key brain areas related to defensive responses, including the dorsal periaqueductal grey, bed nucleus of the stria terminalis and medial prefrontal cortex. Other effects, such as anti-compulsive, increased extinction and impaired reconsolidation of aversive memories, and facilitation of adult hippocampal neurogenesis could depend on potentiation of anandamidemediated neurotransmission. Finally, activation of TRPV1 channels may help us to explain the antipsychotic effect and the bell-shaped dose-response curves commonly observed with CBD. Considering its safety profile and wide range of therapeutic potential, however, further studies are needed to investigate the involvement of other possible mechanisms (e.g. inhibition of adenosine uptake, inverse agonism at CB2 receptor, CB1 receptor antagonism, GPR55 antagonism, PPARg receptors agonism, intracellular (Ca 2þ ) increase, etc.), on CBD behavioural effects.

show abstract

Section: Cannabidiol and Psychosissupporting

confidence: 73%

Multiple mechanisms involved in the large-spectrum therapeutic potential of cannabidiol in psychiatric disorders

Campos

Moreira

Gomes

et al. 2012

Phil. Trans. R. Soc. B

346

237

View full text Add to dashboard Cite

show abstract

“…The opposite effects of delta-9-THC and CBD on functional connectivity provide further complementary evidence for the potential role of CBD as an antipsychotic Leweke et al, 2012;Morgan and Curran, 2008;Morgan et al, 2010b;Zuardi et al, 2012) and suggest that the antipsychotic effects of CBD might be related to its effects on brain activation in regions, which have been consistently found to be associated with psychosis, such as the striatum and the temporal cortex.…”

Section: Discussionmentioning

confidence: 97%

“…Delta-9-tetrahydrocannabiol (delta-9-THC), the main psychoactive ingredient, is responsible for inducing transient psychotic and anxiety symptoms (Bhattacharyya et al, 2009a;D'Souza et al, 2004). In contrast, cannabidiol (CBD), another major ingredient may have anxiolytic Fusar-Poli et al, 2009) and antipsychotic-like effects ) and may oppose the neural effects of delta-9-THC and block the psychotogenic Morgan and Curran, 2008) and cognitive (Morgan et al, 2010a(Morgan et al, , 2010b effects of delta-9-THC. We have recently reported that the induction of psychotic symptoms by delta-9-THC may be related to its effects on the striatum and the prefrontal cortex, integral components of a network of brain areas involved in processing of salient information (Bhattacharyya et al, 2012c), consistent with emerging evidence regarding the role of aberrant salience attribution in psychosis (Jensen and Kapur, 2009;Palaniyappan and Liddle, 2012).…”

Section: Introductionmentioning

confidence: 99%

Cannabinoid Modulation of Functional Connectivity within Regions Processing Attentional Salience

Bhattacharyya

Falkenberg

Martín‐Santos

et al. 2014

Neuropsychopharmacol

102

View full text Add to dashboard Cite

There is now considerable evidence to support the hypothesis that psychotic symptoms are the result of abnormal salience attribution, and that the attribution of salience is largely mediated through the prefrontal cortex, the striatum, and the hippocampus. Although these areas show differential activation under the influence of delta-9-tetrahydrocannabinol (delta-9-THC) and cannabidiol (CBD), the two major derivatives of cannabis sativa, little is known about the effects of these cannabinoids on the functional connectivity between these regions. We investigated this in healthy occasional cannabis users by employing event-related functional magnetic resonance imaging (fMRI) following oral administration of delta-9-THC, CBD, or a placebo capsule. Employing a seed cluster-based functional connectivity analysis that involved using the average time series from each seed cluster for a whole-brain correlational analysis, we investigated the effect of drug condition on functional connectivity between the seed clusters and the rest of the brain during an oddball salience processing task. Relative to the placebo condition, delta-9-THC and CBD had opposite effects on the functional connectivity between the dorsal striatum, the prefrontal cortex, and the hippocampus. Delta-9-THC reduced fronto-striatal connectivity, which was related to its effect on task performance, whereas this connection was enhanced by CBD. Conversely, mediotemporal-prefrontal connectivity was enhanced by delta-9-THC and reduced by CBD. Our results suggest that the functional integration of brain regions involved in salience processing is differentially modulated by single doses of delta-9-THC and CBD and that this relates to the processing of salient stimuli.

show abstract

“…Epidemiological studies of various neuropsychiatric disorders indicate that a higher CBD content in chronically consumed cannabis may protect against adverse effects of THC, including psychotic symptoms, drug cravings, memory loss, and hippocampal gray matter loss [115][116][117][118] (reviewed in [119]). As THC acutely induces anxiety, this pattern may also be evident for chronic anxiety symptoms.…”

Section: Evidence From Epidemiological and Chronic Studiesmentioning

confidence: 99%

Cannabidiol as a Potential Treatment for Anxiety Disorders

et al. 2015

View full text Add to dashboard Cite

Cannabidiol (CBD), a Cannabis sativa constituent, is a pharmacologically broad-spectrum drug that in recent years has drawn increasing interest as a treatment for a range of neuropsychiatric disorders. The purpose of the current review is to determine CBD's potential as a treatment for anxiety-related disorders, by assessing evidence from preclinical, human experimental, clinical, and epidemiological studies. We found that existing preclinical evidence strongly supports CBD as a treatment for generalized anxiety disorder, panic disorder, social anxiety disorder, obsessive-compulsive disorder, and post-traumatic stress disorder when administered acutely; however, few studies have investigated chronic CBD dosing. Likewise, evidence from human studies supports an anxiolytic role of CBD, but is currently limited to acute dosing, also with few studies in clinical populations. Overall, current evidence indicates CBD has considerable potential as a treatment for multiple anxiety disorders, with need for further study of chronic and therapeutic effects in relevant clinical populations.

show abstract

Effects of cannabidiol on schizophrenia-like symptoms in people who use cannabis

Cited by 261 publications

References 12 publications

Multiple mechanisms involved in the large-spectrum therapeutic potential of cannabidiol in psychiatric disorders

Multiple mechanisms involved in the large-spectrum therapeutic potential of cannabidiol in psychiatric disorders

Cannabinoid Modulation of Functional Connectivity within Regions Processing Attentional Salience

Cannabidiol as a Potential Treatment for Anxiety Disorders

Contact Info

Product

Resources

About